Price to sales forward of Nuvalent, Inc. Class A – LS:A3CWDU
This article provides financial data for Nuvalent, Inc. Class A (LS:A3CWDU) focusing
Enterprise value to EBIT forward of Nuvalent, Inc. Class A – LS:A3CWDU
This article provides financial information for Nuvalent, Inc. Class A (LS:A3CWDU), specifically its enterprise value to EBIT forward. It is presented on the TradingView platform, which offers various market data and analysis tools for investors. The content is primarily a data point rather than a detailed analysis.
Price to earnings forward of Nuvalent, Inc. Class A – LSX:A3CWDU
This page provides financial information for Nuvalent, Inc. Class A (LSX:A3CWDU), specifically its forward price-to-earnings ratio. The data presented is from TradingView, with market data from ICE Data Services and reference data from FactSet. The article includes copyright information for the various data providers.
Price to book forward of Nuvalent, Inc. Class A – LS:A3CWDU
This article provides financial data for Nuvalent, Inc. Class A (LS:A3CWDU), focusing on its "Price to book forward" metric. It appears to be a snapshot from a financial data platform like TradingView, offering an overview of the company's financials without further analysis.
Price to book forward of Nuvalent, Inc. Class A – LSX:A3CWDU
This article provides financial information for Nuvalent, Inc. Class A, traded on the Lang & Schwarz Exchange under the symbol A3CWDU. It focuses on the "Price to book forward" metric, indicating that the market is closed and no trades have occurred for this specific data point. The content also notes the sources for market and reference data, including ICE Data Services and FactSet.
Enterprise value to revenue forward of Nuvalent, Inc. Class A – LSX:A3CWDU
This article focuses on the enterprise value to revenue forward for Nuvalent, Inc. Class A (LSX:A3CWDU). It appears to be a financial data point provided by TradingView, indicating no trades and a closed market for this specific security. The content primarily lists various functionalities and services offered by TradingView.
Nuvalent, Inc. Class A Revenue Breakdown – LS:A3CWDU
This article provides a financial overview of Nuvalent, Inc. Class A (A3CWDU) on TradingView. It indicates that the market is closed with no current trades. The article focuses on the financial data and segment performance for the company, accessible through the platform's tools.
Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares
A Deerfield-affiliated investor group, led by James E. Flynn, has filed an amended Schedule 13G (Amendment No. 7) for Nuvalent, Inc. (NUVL). The filing indicates that the group now beneficially owns 0 shares of Nuvalent Class A common stock, translating to 0.0% of the class. This confirms that the Deerfield entities no longer hold a reportable beneficial stake (5% or more) in Nuvalent and possess no sole or shared voting or dispositive power over the shares.
[Form 4] Nuvalent, Inc. Insider Trading Activity
Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, reported significant merger-related equity transactions. These involved the tender of 17,017 shares of Class A Common Stock at $124.00 per share as part of a tender offer by a GlaxoSmithKline affiliate, which was followed by a merger. Additionally, her restricted stock units, performance stock units (14,350 vested), and stock options were cancelled and converted into cash rights based on the Offer Price.
Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout
Nuvalent, Inc. director Sapna Srivastava has disposed of equity tied to a cash tender offer and merger with a GlaxoSmithKline affiliate. She tendered 5,146 shares of Class A Common Stock at $124.00 per share, and had 3,444 restricted stock units and several stock option grants cancelled and converted into cash rights under the Merger Agreement. After these transactions, her reported positions in these securities are zero, reflecting the completion of the acquisition by GSK.
Nuvalent, Inc. (NUVL) CEO equity converted in $124 GSK tender offer
Nuvalent, Inc.'s President and CEO, James Richard Porter, converted all his equity holdings, including 203,529 Class A shares, RSUs, PSUs, and stock options, into cash as part of a tender offer and subsequent merger with an affiliate of GSK plc. The shares were tendered at $124.00 per share, resulting in zero remaining holdings of Nuvalent equity securities for the CEO after the transaction. The conversion was executed according to the terms of the Agreement and Plan of Merger dated June 9, 2026.
Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs
Nuvalent, Inc. CFO Alexandra Balcom reported significant equity transactions stemming from a merger with a GlaxoSmithKline affiliate. She tendered 44,433 shares for $124.00 per share and saw restricted stock units and stock options cancelled and converted into cash at the same offer price. Additionally, 14,350 performance stock units vested as part of the merger terms.
Nuvalent (NASDAQ: NUVL) director logs $124 tender-offer disposals
Nuvalent Director Wheeler Cameron reported the disposition of 5,146 Class A shares at $124.00 each, along with 3,444 RSUs and several stock option grants, related to GlaxoSmithKline's tender offer and subsequent merger. These transactions resulted in Cameron's reported holdings in these Nuvalent securities falling to zero. He disclaims pecuniary interest and beneficial ownership, stating the securities were held for the benefit and at the direction of Deerfield Management Company, of which he is a partner.
Nuvalent (NUVL) director exits equity as GSK affiliate pays $124 per share
Nuvalent's director, Grant C. Bogle, cashed out his equity holdings in connection with the company's acquisition by a GlaxoSmithKline affiliate. The acquisition involved a tender offer at $124.00 per share, resulting in Nuvalent becoming a wholly owned subsidiary. Bogle disposed of Class A Common Stock, restricted stock units, and stock options, leaving him with zero shares of the reported securities.
Nuvalent (NUVL) director equity cashed out in $124 GSK buyout
Nuvalent's director, Anna Protopapas, reported dispositions of her equity holdings in connection with GlaxoSmithKline's tender offer to acquire all outstanding Nuvalent stock for $124.00 per share. Her 5,146 Class A shares, 3,444 restricted stock units, and multiple stock options were tendered or converted into cash rights as Nuvalent became a wholly owned subsidiary of GlaxoSmithKline LLC. Following these transactions, her reported holdings in these securities were reduced to zero.
Nuvalent (NASDAQ: NUVL) moves to remove Class A stock from Nasdaq
Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 25 to delist its Class A Common Stock from the Nasdaq Stock Market LLC, indicating a voluntary withdrawal from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. This action signifies that both Nasdaq and Nuvalent have complied with the necessary rules for the removal. The delisting can lead to reduced visibility, lower trading volume, and wider price swings for investors.
Nuvalent (NASDAQ: NUVL) tender offer clears $124 cash merger path
Nuvalent, Inc. announced the final results of the tender offer by Harmony Row Acquisition Co., a subsidiary of GlaxoSmithKline LLC, to acquire all outstanding shares for $124.00 per share. Approximately 91.3% of Nuvalent's shares were validly tendered, satisfying the minimum tender condition and paving the way for the acquisition to be completed via a merger. Following the merger, Nuvalent's shares will be delisted from Nasdaq and deregistered.
Nuvalent CSO Henry Pelish sells $261,362 in stock By Investing.com
Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of Class A Common Stock for $261,362, executed under a Rule 10b5-1 trading plan to cover tax obligations. This sale occurred as Nuvalent shares approached a 52-week high, coinciding with GSK's announced acquisition of Nuvalent for $10.6 billion. The acquisition, valued at $124 per share, led to various analyst downgrades despite the stock's strong performance and promising drug candidates.
Nuvalent CSO Henry Pelish sells $261,362 in stock
Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of the company's Class A Common Stock for $261,362 on July 9, 2026. This transaction was part of a pre-established trading plan, often used to cover tax obligations from equity awards, and occurred as Nuvalent's stock trades near its 52-week high, having returned 51% over the past year. The sale follows GSK's announcement of a $10.6 billion acquisition offer for Nuvalent, which has led to analyst downgrades and a shift in the stock's valuation.
Nuvalent, Inc. (NUVL) — HSR waiting period cleared; $124/ share cash offer remains subject to closing conditions
Nuvalent, Inc. (NUVL) announced that the Hart-Scott-Rodino (HSR) Act waiting period for its tender offer with Harmony Row Acquisition Co./GlaxoSmithKline LLC expired on July 9, 2026. This satisfies one key closing condition for the $124 per share cash offer, though the overall offer and merger remain subject to other outstanding closing conditions. The company filed an amendment to its Schedule 14D-9 to reflect this development.
Nuvalent Inc. (NUVL) — GSK’s Harmony Row clears HSR; $124 cash offer proceeds
The article reports that the HSR waiting period for GSK’s Harmony Row Acquisition Co.'s tender offer to acquire Nuvalent Inc. (NUVL) has expired, satisfying a key regulatory condition. Harmony Row Acquisition Co., GlaxoSmithKline LLC, and GSK plc are offering $124.00 per share in cash for all outstanding Class A and Class B shares of Nuvalent. This clearance allows the acquisition process to move forward, with the full terms detailed in the Offer to Purchase and Letter of Transmittal documents.
NUVL (NASDAQ: NUVL) insider sale notice for 2,111 Class A shares
Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 144 indicating a proposed sale of 2,111 shares of Class A Common Stock, valued at $261,358.43, related to Restricted Stock Unit Vesting on July 9, 2026. The filing also revealed that 3,093 shares, totaling $323,169.86, were sold in the preceding three months. This notice is a regulatory disclosure of an intended resale, with actual execution details to be confirmed by subsequent filings.
Nuvalent president and CEO Porter sells $3.7m in shares By Investing.com
Nuvalent (NASDAQ:NUVL) President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for approximately $3.71 million on July 6, 2026, while concurrently exercising options to acquire 30,000 shares. This transaction occurred as the stock traded near its 52-week high, following its significant return over the past year. The sale took place after GSK announced a $10.6 billion acquisition of Nuvalent, leading to rating downgrades from UBS and Bernstein due to the deal.
Nuvalent (NUVL) CEO executes 30K-share option exercise and open-market sale under 10b5-1 plan
Nuvalent, Inc. President and CEO James Richard Porter executed a pre-planned transaction, exercising options for 30,000 shares of Class A Common Stock at $18.93 per share and simultaneously selling those 30,000 shares in the open market at a weighted average price of $123.72 per share. These transactions were carried out under a Rule 10b5-1 trading plan adopted on December 4, 2025, to ensure compliance and transparency. Following these trades, Porter directly holds 324,879 shares of Class A Common Stock.
FMR LLC discloses 1,417,590 shares in Nuvalent (NASDAQ: NUVL)
FMR LLC has filed an Amendment No. 5 to Schedule 13G/A, revealing a beneficial ownership of 1,417,590.47 shares of Nuvalent Inc. Class A common stock, which accounts for 1.9% of the total class. The filing indicates sole voting power over 1,402,750 shares and sole dispositive power over 1,417,590.47 shares. This represents a modest and passive stake, maintaining a non-control holding as it is under the 5% threshold.
Nuvalent president and CEO Porter sells $3.7m in shares By Investing.com
Nuvalent (NASDAQ:NUVL) President and CEO James Richard Porter sold 30,000 shares of the company's Class A Common Stock for approximately $3.71 million on July 6, 2026, under a Rule 10b5-1 trading plan. Concurrently, he exercised options to acquire 30,000 shares. This comes amidst GSK's $10.6 billion agreement to acquire Nuvalent, leading analysts to downgrade the stock.
Nuvalent (NUVL) supplements disclosures as $124 cash offer proceeds
Nuvalent, Inc. amended its Schedule 14D-9 to provide supplementary disclosures regarding the recommended $124.00 per share cash tender offer by a GlaxoSmithKline subsidiary. This amendment includes additional financial details, management forecasts, and Centerview valuation analyses, despite the company denying the legal merit of 11 demand letters challenging its initial disclosures. The voluntary supplement aims to prevent transactional delays and offers further context to the offer price by comparing it against various modeled outcomes.
Nuvalent (NUVL) CDO exercises options and sells 23,000 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options for 23,000 shares of Class A Common Stock on July 1, 2026, at exercise prices of $72.35 and $18.93 per share. Immediately after, she sold all 23,000 shares in an open-market transaction at a weighted average price of $123.59 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024, leaving her with 58,117 directly owned shares.
Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan
Nuvalent, Inc.'s CFO, Alexandra Balcom, exercised stock options for 11,430 shares and subsequently sold the same number of shares (11,430) at a weighted average price of $123.58 per share. These transactions were executed on July 1, 2026, under a Rule 10b5-1 trading plan adopted in December 2025. Following these trades, Balcom directly holds 85,533 shares and retains additional stock options.
NUVL (NASDAQ: NUVL) Form 144 lists insider sale of Class A Common
Nuvalent, Inc. (NUVL) has filed a Form 144 with the SEC, indicating a proposed insider sale of Class A Common shares via NQ Stock Options, with J.P. Morgan Securities LLC named as the broker. The filing also details multiple past sales attributed to Alexandra Balcom, occurring between March and June 2026. This notice provides transparency regarding planned and previous insider transactions, with the proposed sale entry date listed as July 1, 2026.
Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares at $27.85 per share and subsequently sold those 5,500 shares in the open market for a weighted average price of $123.51 per share. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following the sale, Noci directly holds 58,117 shares of Nuvalent Class A Common Stock.
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share
GSK plc has launched a tender offer to acquire Nuvalent, Inc. for $124 per share in cash, following a merger agreement signed on June 9, 2026. This move represents a significant step in GSK's strategic acquisitions. Additionally, GSK's ViiV Healthcare has introduced the PrEP Wisdom campaign to enhance understanding of long-acting injectable HIV prevention.
Enterprise value to revenue forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, specifically its enterprise value to revenue (forward) metric. The content indicates that the market was closed and no trades were made for this stock. The data is provided by ICE Data Services and FactSet Research Systems Inc.
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK) for $124.00 per share in cash. KSF aims to determine if the consideration and the sale process are adequate, or if the Company is undervalued. Shareholders concerned about the transaction are encouraged to contact KSF for legal consultation.
Price to book forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange (FWB:5AX). It specifically highlights the "Price to book forward" metric. The content itself seems to be a placeholder or a snippet from a financial data platform, showing no specific numerical values for the metric.
Nuvalent, Inc. Class A Actuals & Estimates (NASDAQ:NUVL)
This article provides an overview of Nuvalent, Inc. (NASDAQ: NUVL) stock's actuals and estimates, including its current stock price, historical performance, analyst forecasts, and various financial metrics. It details the company's market capitalization, earnings per share, revenue, net income, and upcoming earnings report date. The article also addresses frequently asked questions about the stock's volatility, dividend policy, and how to trade its shares.
Price to earnings forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol FWB:5AX. It specifically highlights the "Price to earnings forward" metric for the company. The content appears to be a financial data page from TradingView, focusing on key financial metrics for this pharmaceutical stock.
Enterprise value to EBITDA forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A (FWB:5AX), specifically its enterprise value to EBITDA forward. It notes that the market was closed with no trades. The data is made available through TradingView, sourcing information from ICE Data Services and FactSet.
GSK (NYSE: GSK) moves to acquire Nuvalent with $124/share cash tender offer
GSK has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. This acquisition, made through its subsidiary Harmony Row Acquisition Co., is structured to be followed by a merger, making Nuvalent a wholly-owned subsidiary of GSK LLC. Nuvalent's board has recommended that its stockholders accept the offer, which is set to expire on July 14, 2026, and is contingent on a minimum tender condition and regulatory approvals.
GSK (NUVL) bidders launch $124.00 cash tender for Nuvalent shares
Harmony Row Acquisition Co., a subsidiary of GlaxoSmithKline LLC and GSK plc, has launched a cash tender offer to acquire all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share. This offer is detailed in an amended Schedule TO filing, which incorporates the Offer to Purchase and Letter of Transmittal dated June 24, 2026, and a press release from GSK plc. The transaction provides immediate liquidity to Nuvalent shareholders at a fixed price, with the offer being net to sellers and subject to conditions outlined in the Merger Agreement.
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSK has commenced a tender offer to acquire all outstanding shares of Nuvalent, Inc. for $124.00 per share in cash. The acquisition will proceed through a direct wholly-owned subsidiary, Harmony Row Acquisition Co., and will lead to Nuvalent becoming a wholly-owned subsidiary of GSK LLC. Nuvalent's Board of Directors recommends that stockholders accept the offer, which is set to expire on July 14, 2026, subject to certain conditions.
GSK plc (NUVL) offers $124.00 per share in cash tender for Nuvalent
GSK plc, GlaxoSmithKline LLC, and Harmony Row Acquisition Co. are tendering an offer to purchase all outstanding Class A and Class B shares of Nuvalent, Inc. for $124.00 per share in cash. The offer, detailed in a Schedule TO filing, is subject to the terms of the Offer to Purchase and an Agreement and Plan of Merger dated June 9, 2026. As of June 17, 2026, Nuvalent had 73,899,592 Class A shares and 5,435,254 Class B shares outstanding.
Nuvalent (NUVL) director Ron Squarer receives 3,444 RSUs in equity award
Nuvalent (NUVL) director Ron Squarer was granted an equity award of 3,444 restricted stock units (RSUs) on June 16, 2026. These RSUs, which convert into Class A Common Stock at no purchase price, will vest in full on the earlier of June 16, 2027, or the date of the next annual stockholders' meeting, provided Squarer continues his service. Following this transaction, Squarer's direct holdings in Nuvalent total 6,281 shares.
Nuvalent (NUVL) director Oliger awarded 3,444 RSUs, total holdings 7,415 shares
Nuvalent, Inc. director Christy J. Oliger was granted 3,444 Class A Common Stock Restricted Stock Units (RSUs) as compensation, bringing her total direct holdings to 7,415 shares. These RSUs vest in full on the earlier of June 16, 2027, or the company's next annual stockholder meeting, contingent on her continued service. The transaction was reported in a Form 4 filing, indicating an acquisition of equity-based compensation rather than a market trade.
Nuvalent (NUVL) director Anna Protopapas receives 3,444 RSUs in equity grant
Nuvalent, Inc. director Anna Protopapas was granted 3,444 restricted stock units (RSUs) of Class A Common Stock, as disclosed in a Form 4 filing. The grant, valued at $0.00 per share, is a compensation award and not a market transaction. Following this award, Protopapas directly holds 8,590 shares, with the RSUs scheduled to vest on June 16, 2027, or at the next annual shareholders' meeting, whichever comes first.
Nuvalent (NUVL) director granted 3,444 RSUs in new equity award
Nuvalent, Inc. director Sapna Srivastava was granted 3,444 restricted stock units (RSUs) of Class A Common Stock as a new equity award. These RSUs will vest in full on the earlier of June 16, 2027, or the company's next annual meeting, provided she continues her service. Following this grant, Srivastava directly holds 8,590 shares of Class A Common Stock.
Nuvalent (NUVL) director reports 3,444-share RSU equity award holding 8,590 total
Nuvalent, Inc. director Cameron Wheeler was granted 3,444 shares of Class A Common Stock in the form of restricted stock units (RSUs), bringing his total reported RSU holding to 8,590 shares. The award was granted at no cash cost and vests in full on the earlier of June 16, 2027, or the company's next annual stockholder meeting, contingent on continued service. Wheeler, a partner with Deerfield Management Company, L.P., holds these securities for Deerfield's benefit and disclaims pecuniary interest.
Nuvalent (NUVL) director Grant C. Bogle receives 3,444 RSU award
Nuvalent, Inc. director Grant C. Bogle was granted 3,444 restricted stock units (RSUs) of Class A Common Stock as compensation, not a market purchase. The RSUs, valued at $0.00 per share, will vest fully on June 16, 2027, or at the next annual stockholders' meeting, provided Bogle remains with the company. This award increases his direct holdings to 9,291 shares.
Director at Nuvalent (NUVL) receives 3,444 RSUs in equity grant
Nuvalent, Inc. director Michael L. Meyers received an equity grant of 3,444 restricted stock units (RSUs) of Class A Common Stock at no cash cost. These RSUs will vest on the earlier of June 16, 2027, or the next annual stockholder meeting, contingent on his continued service. Following this grant, Meyers directly holds 8,590 shares of Nuvalent.
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Nuvalent, Inc. (NASDAQ:NUVL) shares surged by 38.2% in pre-market trading after GSK announced an agreement to acquire the company for $10.6 billion, representing a 40% premium. The article also lists other stocks experiencing significant pre-market movements, both gains and losses, influenced by various corporate announcements and market dynamics.
